All In Biotech

Free tool

FAERS Monitor: Rinvoq Lq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218347 or its brand name (Rinvoq Lq, Upadacitinib). Reports on generic versions are filed under their own applications.

Reports

85,284

Serious

58,460

69% of reports

Hospitalization

21,428

Death reported

3,196

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pain5,607
  • arthralgia5,049
  • drug ineffective4,961
  • rheumatoid arthritis3,494
  • covid-193,238
  • pain in extremity2,951
  • fatigue2,855
  • surgery2,719
  • fall2,624
  • headache2,052
  • pneumonia2,046
  • death2,040
  • therapy interrupted1,894
  • diarrhoea1,889
  • back pain1,833

Reports by year received

View as table
YearReports
20161
20175
20187
2019221
20202,841
20215,924
202216,500
202315,076
202415,234
202517,249
202612,226

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,968,875 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
surgerySignal2,71911.911.526,065
rheumatoid arthritisSignal3,4947.87.520,175
therapy interruptedSignal1,8946.76.48,942
covid-19Signal3,2384.64.59,082
arthralgiaSignal5,0493.02.96,870
pain in extremitySignal2,9512.52.42,628
painSignal5,6072.32.24,031
back pain1,8332.01.9855
fall2,6242.01.91,227
pneumonia2,0461.61.5417
drug ineffective4,9610.90.929
fatigue2,8550.90.930
headache2,0520.80.898
diarrhoea1,8890.70.7210
death2,0400.60.6633

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.